AU2002251257B2 - Methods of Using O6-alkylguanine-DNA Alkyltransferases - Google Patents
Methods of Using O6-alkylguanine-DNA Alkyltransferases Download PDFInfo
- Publication number
- AU2002251257B2 AU2002251257B2 AU2002251257A AU2002251257A AU2002251257B2 AU 2002251257 B2 AU2002251257 B2 AU 2002251257B2 AU 2002251257 A AU2002251257 A AU 2002251257A AU 2002251257 A AU2002251257 A AU 2002251257A AU 2002251257 B2 AU2002251257 B2 AU 2002251257B2
- Authority
- AU
- Australia
- Prior art keywords
- agt
- fusion protein
- label
- protein
- alkylguanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 70
- 108010014722 Alkyl and Aryl Transferases Proteins 0.000 title claims abstract description 30
- 102000002226 Alkyl and Aryl Transferases Human genes 0.000 title claims abstract description 30
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 132
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 132
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 62
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 58
- 239000000758 substrate Substances 0.000 claims abstract description 57
- 238000001727 in vivo Methods 0.000 claims abstract description 19
- 238000012546 transfer Methods 0.000 claims abstract description 17
- 239000000284 extract Substances 0.000 claims abstract description 12
- 235000018102 proteins Nutrition 0.000 claims description 56
- 238000002372 labelling Methods 0.000 claims description 30
- 239000000523 sample Substances 0.000 claims description 20
- 230000004927 fusion Effects 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 12
- 125000005647 linker group Chemical group 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 9
- 238000007792 addition Methods 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 5
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 claims description 5
- XWNJMSJGJFSGRY-UHFFFAOYSA-N 2-(benzylamino)-3,7-dihydropurin-6-one Chemical compound N1C=2N=CNC=2C(=O)N=C1NCC1=CC=CC=C1 XWNJMSJGJFSGRY-UHFFFAOYSA-N 0.000 claims description 4
- 241001529936 Murinae Species 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 230000012743 protein tagging Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 108010078339 DNA alkyltransferase Proteins 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 43
- 238000001514 detection method Methods 0.000 abstract description 6
- 210000001723 extracellular space Anatomy 0.000 abstract description 3
- 230000001580 bacterial effect Effects 0.000 abstract description 2
- 238000004113 cell culture Methods 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 108020004705 Codon Proteins 0.000 description 14
- KRWMERLEINMZFT-UHFFFAOYSA-N O6-benzylguanine Chemical class C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 description 14
- 108091023040 Transcription factor Proteins 0.000 description 14
- 102000040945 Transcription factor Human genes 0.000 description 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 101710188306 Protein Y Proteins 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 150000003384 small molecules Chemical class 0.000 description 8
- 239000013076 target substance Substances 0.000 description 8
- 108010090804 Streptavidin Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- -1 hydroxyl radicals Chemical class 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000004568 DNA-binding Effects 0.000 description 5
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 108020001096 dihydrofolate reductase Proteins 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 210000005253 yeast cell Anatomy 0.000 description 5
- 108090001008 Avidin Proteins 0.000 description 4
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229940072107 ascorbate Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006287 biotinylation Effects 0.000 description 3
- 238000007413 biotinylation Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 3
- 229940107698 malachite green Drugs 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101100385969 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYC8 gene Proteins 0.000 description 2
- 101100276456 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ssn6 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 108091006004 biotinylated proteins Proteins 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000003498 protein array Methods 0.000 description 2
- 231100000489 sensitizer Toxicity 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical group 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 108091006058 immobilized fusion proteins Proteins 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 238000010399 three-hybrid screening Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28276601P | 2001-04-10 | 2001-04-10 | |
| US60/282,766 | 2001-04-10 | ||
| PCT/GB2002/001636 WO2002083937A2 (en) | 2001-04-10 | 2002-04-05 | Methods using o6-alkylguanine-dna alkyltransferases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002251257A1 AU2002251257A1 (en) | 2003-04-17 |
| AU2002251257B2 true AU2002251257B2 (en) | 2007-08-30 |
Family
ID=23083030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002251257A Ceased AU2002251257B2 (en) | 2001-04-10 | 2002-04-05 | Methods of Using O6-alkylguanine-DNA Alkyltransferases |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7939284B2 (enExample) |
| EP (4) | EP2037271B1 (enExample) |
| JP (2) | JP4195815B2 (enExample) |
| KR (1) | KR20040039194A (enExample) |
| CN (2) | CN1975422B (enExample) |
| AT (3) | ATE419378T1 (enExample) |
| AU (1) | AU2002251257B2 (enExample) |
| CA (1) | CA2443570A1 (enExample) |
| DE (3) | DE60230689D1 (enExample) |
| DK (1) | DK1410023T3 (enExample) |
| IL (1) | IL157880A0 (enExample) |
| NZ (3) | NZ537939A (enExample) |
| WO (1) | WO2002083937A2 (enExample) |
| ZA (1) | ZA200307442B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2501061A1 (en) * | 2002-10-03 | 2004-04-15 | Ecole Polytechnique Federale De Lausanne (Epfl) | Protein labelling with o6-alkylguanine-dna alkyltransferase |
| US7799524B2 (en) | 2002-10-03 | 2010-09-21 | Ecole Polytechnique Ferdeale de Lausanne | Substrates for O6-alkylguanina-DNA alkyltransferase |
| US7429472B2 (en) | 2003-01-31 | 2008-09-30 | Promega Corporation | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule |
| EP2341134B1 (en) | 2003-01-31 | 2014-08-27 | Promega Corporation | Covalent tethering of functional groups to proteins |
| WO2004104588A1 (en) * | 2003-05-23 | 2004-12-02 | Epfl - Ecole Polytechnique Federale De Lausanne | Methods for protein labeling based on acyl carrier protein |
| JP2007526282A (ja) * | 2004-03-02 | 2007-09-13 | ウペエフエル・エコル・ポリテクニック・フェデラル・ドゥ・ローザンヌ | Ｏ６−アルキルグアニンｄｎａアルキルトランスフェラーゼ特異的基質 |
| US7888090B2 (en) | 2004-03-02 | 2011-02-15 | Ecole Polytechnique Federale De Lausanne | Mutants of O6-alkylguanine-DNA alkyltransferase |
| US7425436B2 (en) | 2004-07-30 | 2008-09-16 | Promega Corporation | Covalent tethering of functional groups to proteins and substrates therefor |
| US7825096B2 (en) | 2004-09-08 | 2010-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs |
| US7273714B2 (en) * | 2005-03-11 | 2007-09-25 | Vion Pharmaceuticals, Inc. | Alkylguanyltransferase assays |
| US8178314B2 (en) | 2005-04-27 | 2012-05-15 | Covalys Biosciences Ag | Pyrimidines reacting with O6-alkylguanine-DNA alkyltransferase fusion protein and method for detecting protein |
| FR2890174B1 (fr) | 2005-08-30 | 2009-04-24 | Cis Bio Internat Sa | Procede pour la mise en evidence d'un processus biologique par mesure d'un fret |
| FR2890446B1 (fr) | 2005-09-05 | 2008-04-18 | Cis Bio Internat Sa | Methode de detection d'interaction intracellulaire entre bio-molecules |
| EP2405272B1 (en) | 2006-06-30 | 2015-01-14 | DiscoveRx Corporation | Detectable nucleic acid tag |
| CA2667697A1 (en) | 2006-10-30 | 2008-05-08 | Promega Corporation | Mutant hydrolase proteins with enhanced kinetics and functional expression |
| US7897737B2 (en) | 2006-12-05 | 2011-03-01 | Lasergen, Inc. | 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing |
| JP5513122B2 (ja) * | 2006-12-05 | 2014-06-04 | レーザーゲン インコーポレイテッド | 光開裂性標識ヌクレオチドとヌクレオシドおよび標識ヌクレオチドとヌクレオシドならびにｄｎａ配列決定におけるそれらの使用法 |
| EP1978093A1 (en) * | 2007-04-04 | 2008-10-08 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Method of crosslinking two objects of interest |
| GB0711560D0 (en) | 2007-06-14 | 2007-07-25 | Innova Biosciences Ltd | Improvements in or relating to production of conjugates |
| ATE522810T1 (de) * | 2007-10-29 | 2011-09-15 | New England Biolabs Inc | Verfahren und zusammensetzungen zum nachweis und zur anreicherung kleiner ziel-rnas |
| EP2093564A1 (en) | 2008-02-25 | 2009-08-26 | Technische Universität Dresden Medizinische Fakultät Carl Gustav Carus | Method for distinguishing secretory granules of different ages |
| BRPI0915173B8 (pt) | 2008-06-11 | 2021-05-25 | Agilent Technologies Inc | compostos de nucleotídeos e nucleosídeos e método de sequenciamento de um ácido nucleico-alvo |
| FR2936245B1 (fr) * | 2008-09-23 | 2012-07-06 | Cis Bio Int | Nouveaux substrats d'o6-alkylguanine-adn alkyltransferase et ses mutants. |
| WO2011091146A1 (en) | 2010-01-20 | 2011-07-28 | New England Biolabs, Inc. | Compositions, methods and related uses for cleaving modified dna |
| JP6043288B2 (ja) | 2010-09-15 | 2016-12-14 | エンダセア， インコーポレイテッド | 時間分解蛍光ベースのアッセイによるリポ多糖の測定のための使用方法およびキット |
| MX342195B (es) | 2011-09-13 | 2016-09-20 | Lasergen Inc | Nucleótidos de terminación de rápida fotodescomposición 5-metoxi, 3' -oh no bloqueados y métodos para secuenciación de ácido nucleico. |
| JP6215223B2 (ja) * | 2011-12-09 | 2017-10-18 | アンスティテュ・パストゥール | マルチプレックス免疫スクリーニングアッセイ |
| US9200260B2 (en) | 2012-03-15 | 2015-12-01 | New England Biolabs, Inc. | Compositions and methods for the transfer of a hexosamine to a modified nucleotide in a nucleic acid |
| US9567632B2 (en) | 2013-03-19 | 2017-02-14 | New England Biolabs, Inc. | Enrichment of target sequences |
| JP5781589B2 (ja) * | 2013-12-20 | 2015-09-24 | レーザーゲン インコーポレイテッド | 光開裂性標識ヌクレオチドとヌクレオシドおよび標識ヌクレオチドとヌクレオシドならびにｄｎａ配列決定におけるそれらの使用法 |
| US10080787B2 (en) | 2014-07-02 | 2018-09-25 | New England Biolabs, Inc. | Universal N-glycan binding reagent |
| WO2016093838A1 (en) | 2014-12-11 | 2016-06-16 | New England Biolabs, Inc. | Enrichment of target sequences |
| CN104844710B (zh) * | 2015-04-13 | 2018-02-02 | 西北大学 | 定向固定化pega复合型树酯的制备方法及应用 |
| KR20190015461A (ko) | 2016-06-06 | 2019-02-13 | 노쓰웨스턴유니버시티 | 융합 단백질 작제물 |
| CN113444094B (zh) | 2016-07-20 | 2023-12-22 | 纳莹(上海)生物科技有限公司 | 一种荧光探针及其制备方法和用途 |
| US10934533B1 (en) | 2018-10-10 | 2021-03-02 | New England Biolabs, Inc. | Variant DNA polymerases having improved properties and method for improved isothermal amplification of a target DNA |
| CN111253417B (zh) * | 2019-09-04 | 2022-03-25 | 大连民族大学 | 一种嘌呤衍生物的合成及应用 |
| WO2021113290A1 (en) | 2019-12-03 | 2021-06-10 | Alamar Biosciences, Inc. | Nucleic acid linked immune-sandwich assay (nulisa) |
| EP4103701A1 (en) | 2020-02-13 | 2022-12-21 | New England Biolabs, Inc. | Variant family d dna polymerases |
| WO2021163559A1 (en) | 2020-02-13 | 2021-08-19 | New England Biolabs, Inc. | Variant family d dna polymerases |
| EP4118233A1 (en) | 2020-03-12 | 2023-01-18 | New England Biolabs, Inc. | A rapid diagnostic test for lamp |
| CN112010983A (zh) * | 2020-08-11 | 2020-12-01 | 西北大学 | 止咳平喘中药活性成分靶向筛选方法及试剂盒 |
| WO2022040443A2 (en) | 2020-08-21 | 2022-02-24 | New England Biolabs, Inc. | A rapid diagnostic test for lamp |
| US11993792B2 (en) | 2021-05-27 | 2024-05-28 | New England Biolabs, Inc. | DNase I variants, compositions, methods, and kits |
| WO2022250676A1 (en) | 2021-05-27 | 2022-12-01 | New England Biolabs, Inc. | Dnase i variants, compositions, methods, and kits |
| WO2023097226A2 (en) | 2021-11-24 | 2023-06-01 | New England Biolabs, Inc. | Double-stranded dna deaminases |
| WO2023197015A1 (en) | 2022-04-08 | 2023-10-12 | New England Biolabs, Inc. | Compositions and analysis of dephosphorylated oligoribonucleotides |
| EP4658673A1 (en) | 2023-02-01 | 2025-12-10 | New England Biolabs, Inc. | Duplex-specific dnases |
| US20250115953A1 (en) | 2023-10-05 | 2025-04-10 | New England Biolabs, Inc. | Methylcytosine-Selective Deaminases and Uses Thereof |
| WO2025129193A1 (en) | 2023-12-15 | 2025-06-19 | New England Biolabs, Inc. | Glycosyltransferases and related methods |
| WO2025137453A1 (en) | 2023-12-20 | 2025-06-26 | New England Biolabs, Inc. | Compositions, methods, kits, and instruments for analyzing rna structure |
| GB202400129D0 (en) | 2024-01-04 | 2024-02-21 | Cambridge Entpr Ltd | Nucleic acid barcodes |
| WO2025224010A1 (en) | 2024-04-24 | 2025-10-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. | Improved o6-alkylguanine-dna alkyltransferase substrates |
| WO2025227034A1 (en) | 2024-04-26 | 2025-10-30 | New England Biolabs, Inc. | Salt active nuclease compositions and methods |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19903895A1 (de) * | 1999-02-01 | 2000-08-03 | Kai Johnsson | Selektive Immobilisierung und Nachweis der O·6·-Alkylguanin-DNA-Alkyltransferase in der aktiven Form |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9224888D0 (en) * | 1992-11-27 | 1993-01-13 | Univ Singapore | Monoclonal antibody |
| AU697977B2 (en) * | 1993-06-08 | 1998-10-22 | Cancer Research Technology Limited | O6-substituted guanine derivatives, a process for their preparation and their use in treating tumour cells |
-
2002
- 2002-04-05 EP EP08168182A patent/EP2037271B1/en not_active Expired - Lifetime
- 2002-04-05 DK DK02720187T patent/DK1410023T3/da active
- 2002-04-05 JP JP2002582274A patent/JP4195815B2/ja not_active Expired - Lifetime
- 2002-04-05 WO PCT/GB2002/001636 patent/WO2002083937A2/en not_active Ceased
- 2002-04-05 EP EP06111733A patent/EP1696234B1/en not_active Expired - Lifetime
- 2002-04-05 KR KR10-2003-7012899A patent/KR20040039194A/ko not_active Abandoned
- 2002-04-05 CA CA002443570A patent/CA2443570A1/en not_active Abandoned
- 2002-04-05 US US10/474,796 patent/US7939284B2/en not_active Expired - Lifetime
- 2002-04-05 DE DE60230689T patent/DE60230689D1/de not_active Expired - Lifetime
- 2002-04-05 DE DE60237792T patent/DE60237792D1/de not_active Expired - Lifetime
- 2002-04-05 NZ NZ537939A patent/NZ537939A/en unknown
- 2002-04-05 IL IL15788002A patent/IL157880A0/xx not_active IP Right Cessation
- 2002-04-05 AT AT06111733T patent/ATE419378T1/de not_active IP Right Cessation
- 2002-04-05 DE DE60212642T patent/DE60212642T2/de not_active Expired - Lifetime
- 2002-04-05 EP EP02720187A patent/EP1410023B1/en not_active Expired - Lifetime
- 2002-04-05 AT AT02720187T patent/ATE331220T1/de not_active IP Right Cessation
- 2002-04-05 CN CN2006101603317A patent/CN1975422B/zh not_active Expired - Lifetime
- 2002-04-05 EP EP10075132.0A patent/EP2211177B1/en not_active Expired - Lifetime
- 2002-04-05 AT AT08168182T patent/ATE482395T1/de not_active IP Right Cessation
- 2002-04-05 AU AU2002251257A patent/AU2002251257B2/en not_active Ceased
- 2002-04-05 NZ NZ540410A patent/NZ540410A/en unknown
- 2002-04-05 CN CNB028081137A patent/CN1295510C/zh not_active Expired - Lifetime
- 2002-04-05 NZ NZ528594A patent/NZ528594A/en unknown
-
2003
- 2003-09-25 ZA ZA200307442A patent/ZA200307442B/xx unknown
-
2007
- 2007-12-20 JP JP2007328757A patent/JP4226053B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-24 US US13/012,234 patent/US8367361B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19903895A1 (de) * | 1999-02-01 | 2000-08-03 | Kai Johnsson | Selektive Immobilisierung und Nachweis der O·6·-Alkylguanin-DNA-Alkyltransferase in der aktiven Form |
Non-Patent Citations (2)
| Title |
|---|
| Damoiseaux R et al, Chembiochem (2001), vol 2 (4): 285-287 * |
| Vaidyanathan G et al; Bioconjugate Chem (2000); vol 11: 868-875 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002251257B2 (en) | Methods of Using O6-alkylguanine-DNA Alkyltransferases | |
| AU2002251257A1 (en) | Methods of Using O6-alkylguanine-DNA Alkyltransferases | |
| US7666612B2 (en) | Methods for protein labeling based on acyl carrier protein | |
| JP2004532028A5 (enExample) | ||
| US20060292651A1 (en) | Protein labelling with oº-alkylguanine-dna alkyltrnsferase | |
| CN113721023A (zh) | 一种基于Barnase/barstar的生物免疫传感系统及应用 | |
| HK1068406B (en) | Methods using o6 - alkylguanine - dna alkyltransferases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: DELETE THE INVENTOR SIMON JOHN KIDDLE |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |